Rocuronium

50 mg/5 ml vials (IV)

Executive Summary

(May 11, 2022)

Neuromuscular blockade is an essential component of rapid sequence intubation. Rocuronium is becoming the most commonly used non-depolarizing neuromuscular blocking agent (N-NMBA) in the emergency department due to its ability to create excellent intubating conditions compared to other NMBAs, and its superior safety profile over succinylcholine for a variety of clinical conditions when the latter is contraindicated (NMBA table). 

Adult dose for rapid sequence intubation (15, 18)

1.5 mg/kg IV

Adult dose

Adult dose for rapid sequence intubation (15, 18)

Adult dose for paralysis, continuous infusion (11, 16, 19)

Indications

Rocuronium vs succinylcholine for RSI in the ED

Rocuronium trend as the NMB agent of choice in Emergency Medicine

Cautions

Awareness with paralysis in mechanically ventilated patients

Pharmacology

Pregnancy and Lactation

Pregnancy risk classification


Lactation

References

® 2023 EMDrugs. All rights reserved.

contact@emdrugs.com

DISCLAIMER

This website provides general information and discussion about medications, health, and related subjects. The words and other con­tent pro­vided in this website, and in any linked mate­ri­als, are not intended and should not be con­strued as med­ical advice. If the reader or any other per­son has a med­ical con­cern, he or she should con­sult with an appropriately-licensed physi­cian or other legally accredited health care worker in the country that resides or is visiting. 

 

Please do not delay your medical concerns and potential health emergencies by searching information in this website, instead look out for medical opinion in the services that exist with that specific purpose and work under the respective local health-care regulations. 

 

The views expressed on this blog and web­site have no rela­tion to those of any academic, hospital, practice or other insti­tu­tion with which the authors are  affiliated. 

 

For other instances, the authors of this website do not have any conflict of interest with any institution or pharmaceutical company in particular, and do not receive any compensation about any licenced drug mentioned in the website. In the same matter, the website is not intended to recommend any specific patented medication.


EMDrugs Team